Loading
KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Exhibits faster activation and deactivation kinetics and slow inactivation at membrane potentials positive to 240 mV, resulting in the weakest inward rectification.
Open Targets scores its association with cancer at 0.52 (direct and indirect evidence; datatypes literature 0.11, genetic association 0.27, clinical 0.76).
In plain words · KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
KCNH7 (Voltage-gated inwardly rectifying potassium channel KCNH7) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it.
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel.
No product in this corpus aims at KCNH7 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA KCNH7: RNA tissue enhanced (brain 2 nTPM, retina 1 nTPM); no normal tissue stained high. Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 1 specific cancer type at or above 0.5 (Lambert-Eaton myasthenic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas KCNH7 tissue; Open Targets ENSG00000184611 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Ganetzky et al, 1997, "Polynucleotides encoding herg-3 potassium channel". Source.
Sources: HGNC HGNC:18863 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NS40 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000184611 (association with cancer (MONDO_0004992) 0.52; (GraphQL API, CC0))
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Exhibits faster activation and deactivation kinetics and slow inactivation at membrane potentials positive to 240 mV, resulting in the weakest inward rectification. Location: Cell membrane (UniProt). Locus 2q24.2 (HGNC).
RNA: tissue enhanced (brain 2 nTPM, retina 1 nTPM), detected in some normal tissues.
No normal tissue stained high.
No cancer stained high; medium in cervical cancer, ovarian cancer.
HPA KCNH7 tissue · HPA KCNH7 pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"KCNH7" OR ABSTRACT:"KCNH7" OR TITLE:"potassium voltage-gated channel subfamily H member 7" OR ABSTRACT:"potassium voltage-gated channel subfamily H member 7" OR TITLE:"Voltage-gated inwardly rectifying potassium channel KCNH7" OR ABSTRACT:"Voltage-gated inwardly rectifying potassium channel KCNH7" OR TITLE:"Kv11.3" OR ABSTRACT:"Kv11.3" OR TITLE:"HERG3" OR ABSTRACT:"HERG3" OR TITLE:"erg3" OR ABSTRACT:"erg3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KCNH7, not a curated reading list.